TG Therapeutics TGTX Non Cash Compensation Research And Development Expenses
Non Cash Compensation Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept tgtx:NonCashCompensationResearchAndDevelopmentExpenses.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's non cash compensation research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's non cash compensation research and development expenses?
- TG Therapeutics (TGTX) reported non cash compensation research and development expenses of $4.88M in Q1 2026.
- How has TG Therapeutics's non cash compensation research and development expenses changed year-over-year?
- TG Therapeutics's non cash compensation research and development expenses increased by 46.4% year-over-year, from $3.33M to $4.88M.
- What is the long-term trend for TG Therapeutics's non cash compensation research and development expenses?
- Over 4 years (2021 to 2025), TG Therapeutics's non cash compensation research and development expenses has grown at a -8.8% compound annual growth rate (CAGR), from $24.05M to $16.62M.
- What does non cash compensation research and development expenses mean?
- The value of stock-based compensation awarded to research and development staff.
- How do you interpret non cash compensation research and development expenses?
- High levels may indicate aggressive talent retention strategies, though it dilutes existing shareholders.
- How does non cash compensation research and development expenses compare across companies?
- Standard line item for technology and biotech firms using equity to attract specialized scientific talent.